PL2468281T3 - Kompozycja farmaceutyczna zawierająca pochodną chinoliny - Google Patents
Kompozycja farmaceutyczna zawierająca pochodną chinolinyInfo
- Publication number
- PL2468281T3 PL2468281T3 PL10809938T PL10809938T PL2468281T3 PL 2468281 T3 PL2468281 T3 PL 2468281T3 PL 10809938 T PL10809938 T PL 10809938T PL 10809938 T PL10809938 T PL 10809938T PL 2468281 T3 PL2468281 T3 PL 2468281T3
- Authority
- PL
- Poland
- Prior art keywords
- pharmaceutical composition
- containing pharmaceutical
- quinoline derivative
- quinoline
- derivative
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009190145 | 2009-08-19 | ||
| EP10809938.3A EP2468281B1 (en) | 2009-08-19 | 2010-08-16 | Quinoline derivative-containing pharmaceutical composition |
| PCT/JP2010/063804 WO2011021597A1 (ja) | 2009-08-19 | 2010-08-16 | キノリン誘導体含有医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2468281T3 true PL2468281T3 (pl) | 2016-06-30 |
Family
ID=43607048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10809938T PL2468281T3 (pl) | 2009-08-19 | 2010-08-16 | Kompozycja farmaceutyczna zawierająca pochodną chinoliny |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US20120077842A1 (pl) |
| EP (1) | EP2468281B1 (pl) |
| JP (1) | JP5048871B2 (pl) |
| KR (1) | KR101496395B1 (pl) |
| CN (1) | CN102470133B (pl) |
| AU (1) | AU2010285740C1 (pl) |
| BR (1) | BR112012003592B8 (pl) |
| CA (1) | CA2771403C (pl) |
| CL (1) | CL2012000412A1 (pl) |
| CO (1) | CO6440512A2 (pl) |
| CY (1) | CY1117481T1 (pl) |
| DK (1) | DK2468281T3 (pl) |
| ES (1) | ES2564797T3 (pl) |
| HR (1) | HRP20160283T1 (pl) |
| HU (1) | HUE026957T2 (pl) |
| IL (1) | IL217197A (pl) |
| MA (1) | MA33581B1 (pl) |
| ME (1) | ME02359B (pl) |
| MX (2) | MX344927B (pl) |
| MY (1) | MY162940A (pl) |
| NZ (1) | NZ598291A (pl) |
| PE (1) | PE20121030A1 (pl) |
| PL (1) | PL2468281T3 (pl) |
| RS (1) | RS54686B1 (pl) |
| RU (1) | RU2548673C3 (pl) |
| SG (1) | SG178009A1 (pl) |
| SI (1) | SI2468281T1 (pl) |
| SM (1) | SMT201600077B (pl) |
| TH (1) | TH121482A (pl) |
| UA (1) | UA105671C2 (pl) |
| WO (1) | WO2011021597A1 (pl) |
| ZA (1) | ZA201108697B (pl) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1797881B1 (en) | 2004-09-17 | 2009-04-15 | Eisai R&D Management Co., Ltd. | Medicinal composition with improved stability and reduced gelation properties |
| EP2281901B1 (en) * | 2005-08-02 | 2013-11-27 | Eisai R&D Management Co., Ltd. | Anti-tumour pharmaceutical composition with angiogenesis inhibitors |
| CN102716490A (zh) * | 2005-09-01 | 2012-10-10 | 卫材R&D管理有限公司 | 药物组合物的崩解性的改善方法 |
| CN101316590B (zh) | 2005-11-07 | 2011-08-03 | 卫材R&D管理有限公司 | 血管生成抑制剂和c-kit激酶抑制剂的组合使用 |
| EP2036557B1 (en) * | 2006-05-18 | 2015-10-21 | Eisai R&D Management Co., Ltd. | Antitumor agent for thyroid cancer |
| CN101511793B (zh) * | 2006-08-28 | 2011-08-03 | 卫材R&D管理有限公司 | 针对未分化型胃癌的抗肿瘤剂 |
| AU2008211952B2 (en) | 2007-01-29 | 2012-07-19 | Eisai R & D Management Co., Ltd. | Composition for treatment of undifferentiated-type of gastric cancer |
| JP5638244B2 (ja) | 2007-11-09 | 2014-12-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質と抗腫瘍性白金錯体との併用 |
| MX2012014776A (es) | 2010-06-25 | 2013-01-29 | Eisai R&D Man Co Ltd | Agente antitumoral que emplea compuestos con efecto inhibidor de cinasas combinados. |
| MX2013009931A (es) | 2011-04-18 | 2013-10-01 | Eisai R&D Man Co Ltd | Agentes terapeuticos contra tumores. |
| US9945862B2 (en) | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| US9334239B2 (en) | 2012-12-21 | 2016-05-10 | Eisai R&D Management Co., Ltd. | Amorphous form of quinoline derivative, and method for producing same |
| US10517861B2 (en) | 2013-05-14 | 2019-12-31 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| CN106660964B (zh) | 2014-08-28 | 2021-09-03 | 卫材R&D管理有限公司 | 高纯度喹啉衍生物及其生产方法 |
| CN106139156B (zh) * | 2014-11-14 | 2019-01-29 | 江苏恒瑞医药股份有限公司 | 一种含有喹啉衍生物或其盐的药物组合物 |
| PL3263106T3 (pl) | 2015-02-25 | 2024-04-02 | Eisai R&D Management Co., Ltd. | Sposób tłumienia goryczy pochodnej chinoliny |
| KR102662228B1 (ko) | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| CN106075456A (zh) * | 2015-04-27 | 2016-11-09 | 南京圣和药业股份有限公司 | 一种含乐伐替尼的药物组合物及其应用 |
| US10246418B2 (en) * | 2015-05-21 | 2019-04-02 | Crystal Pharmatech Co., Ltd. | Crystal form of lenvatinib methanesulfonate salt and preparation method thereof |
| ES2886107T3 (es) | 2015-06-16 | 2021-12-16 | Prism Biolab Co Ltd | Antineoplásico |
| WO2017028660A1 (zh) * | 2015-08-17 | 2017-02-23 | 江苏恒瑞医药股份有限公司 | 一种含有喹啉衍生物或其盐的药物组合物 |
| AU2016309356B2 (en) | 2015-08-20 | 2021-06-24 | Eisai R&D Management Co., Ltd. | Tumor therapeutic agent |
| RU2606592C1 (ru) * | 2015-10-07 | 2017-01-10 | Открытое Акционерное Общество "Татхимфармпрепараты" | Фармацевтическая композиция, содержащая кальциевую соль розувастатина (варианты) |
| CZ2016240A3 (cs) | 2016-04-27 | 2017-11-08 | Zentiva, K.S. | Soli lenvatinibu |
| MX380144B (es) | 2017-02-08 | 2025-03-12 | Eisai R&D Man Co Ltd | Composicion farmaceutica de tratamiento de tumores. |
| PL3384901T3 (pl) * | 2017-04-04 | 2025-01-13 | Synthon B.V. | Kompozycja farmaceutyczna zawierająca mesylan lenwatynibu |
| CA3061888A1 (en) | 2017-05-16 | 2018-11-22 | Eisai R&D Management Co., Ltd. | Treatment of hepatocellular carcinoma |
| US10583133B2 (en) | 2018-03-12 | 2020-03-10 | Shilpa Medicare Limited | Pharmaceutical compositions of lenvatinib |
| CN110404079B (zh) * | 2018-04-27 | 2023-01-24 | 北京睿创康泰医药研究院有限公司 | 一种不含碳酸盐、低基因毒性杂质含量的喹啉衍生物或其盐的药物组合物 |
| CA3113549A1 (en) | 2018-10-04 | 2020-04-09 | Synthon B.V. | Crystalline forms and processes of lenvatinib besylate |
| EP3632436B1 (en) | 2018-10-04 | 2022-04-20 | Synthon B.V. | Pharmaceutical composition comprising lenvatinib salts |
| CN113087666B (zh) * | 2020-01-09 | 2021-12-14 | 南京正大天晴制药有限公司 | 无定形喹啉甲酰胺衍生物的制备方法 |
| WO2021185006A1 (zh) * | 2020-03-18 | 2021-09-23 | 上海博志研新药物技术有限公司 | 一种仑伐替尼药物组合物、其制备方法及应用 |
| EP4147689A1 (en) | 2021-09-13 | 2023-03-15 | Lotus Pharmaceutical Co., Ltd. | Lenvatinib formulation |
| CN114306271B (zh) * | 2021-11-24 | 2023-04-07 | 石药集团中奇制药技术（石家庄）有限公司 | 一种仑伐替尼组合物 |
| CN115671074B (zh) * | 2022-11-15 | 2024-06-04 | 郑州德迈药业有限公司 | 一种甲磺酸仑伐替尼制剂及其制备方法 |
| EP4424303A1 (en) | 2023-02-28 | 2024-09-04 | Stada Arzneimittel Ag | Lenvatinib composition with improved bioavailability |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5009894A (en) * | 1988-03-07 | 1991-04-23 | Baker Cummins Pharmaceuticals, Inc. | Arrangement for and method of administering a pharmaceutical preparation |
| HU230302B1 (hu) * | 2000-10-20 | 2015-12-28 | Eisai R&D Management Co., Ltd. | Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények |
| EP2596792A1 (en) * | 2002-10-16 | 2013-05-29 | Takeda Pharmaceutical Company Limited | Stable solid preparations |
| JP4749660B2 (ja) * | 2002-10-16 | 2011-08-17 | 武田薬品工業株式会社 | 安定な固形製剤 |
| ES2263015T3 (es) * | 2002-10-21 | 2006-12-01 | Warner-Lambert Company Llc | Derivados de tetrahidroquinolina como antagonistas de crth2. |
| ATE508747T1 (de) * | 2003-03-10 | 2011-05-15 | Eisai R&D Man Co Ltd | C-kit kinase-hemmer |
| JP4648835B2 (ja) | 2003-12-25 | 2011-03-09 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ４−（３−クロロ−４−（シクロプロピルアミノカルボニル）アミノフェノキシ）−７−メトキシ−６−キノリンカルボキサミドの塩またはその溶媒和物の結晶およびそれらの製造方法 |
| EP1797881B1 (en) * | 2004-09-17 | 2009-04-15 | Eisai R&D Management Co., Ltd. | Medicinal composition with improved stability and reduced gelation properties |
| US7550483B2 (en) * | 2005-06-23 | 2009-06-23 | Eisai R&D Management Co., Ltd. | Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for preparing the same |
| CA2606719C (en) * | 2005-06-23 | 2010-08-10 | Eisai R & D Management Co., Ltd. | Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for producing the same |
| AR059066A1 (es) * | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| AU2009221765B2 (en) * | 2008-03-05 | 2015-05-07 | Vicus Therapeutics, Llc | Compositions and methods for mucositis and oncology therapies |
-
2010
- 2010-08-16 AU AU2010285740A patent/AU2010285740C1/en active Active
- 2010-08-16 RS RS20160176A patent/RS54686B1/sr unknown
- 2010-08-16 EP EP10809938.3A patent/EP2468281B1/en active Active
- 2010-08-16 MY MYPI2011700172A patent/MY162940A/en unknown
- 2010-08-16 WO PCT/JP2010/063804 patent/WO2011021597A1/ja not_active Ceased
- 2010-08-16 PL PL10809938T patent/PL2468281T3/pl unknown
- 2010-08-16 ES ES10809938.3T patent/ES2564797T3/es active Active
- 2010-08-16 KR KR1020127003846A patent/KR101496395B1/ko active Active
- 2010-08-16 ME MEP-2016-45A patent/ME02359B/me unknown
- 2010-08-16 UA UAA201203132A patent/UA105671C2/uk unknown
- 2010-08-16 CA CA2771403A patent/CA2771403C/en active Active
- 2010-08-16 HR HRP20160283TT patent/HRP20160283T1/hr unknown
- 2010-08-16 SI SI201031141A patent/SI2468281T1/sl unknown
- 2010-08-16 PE PE2011002081A patent/PE20121030A1/es active IP Right Grant
- 2010-08-16 BR BR112012003592A patent/BR112012003592B8/pt active IP Right Grant
- 2010-08-16 RU RU2012103471A patent/RU2548673C3/ru active Protection Beyond IP Right Term
- 2010-08-16 MX MX2014010594A patent/MX344927B/es unknown
- 2010-08-16 TH TH1001000221A patent/TH121482A/th unknown
- 2010-08-16 MX MX2012002011A patent/MX2012002011A/es unknown
- 2010-08-16 CN CN2010800305086A patent/CN102470133B/zh not_active Ceased
- 2010-08-16 US US13/322,961 patent/US20120077842A1/en not_active Abandoned
- 2010-08-16 DK DK10809938.3T patent/DK2468281T3/en active
- 2010-08-16 SG SG2011086022A patent/SG178009A1/en unknown
- 2010-08-16 NZ NZ598291A patent/NZ598291A/xx unknown
- 2010-08-16 JP JP2011527665A patent/JP5048871B2/ja active Active
- 2010-08-16 HU HUE10809938A patent/HUE026957T2/en unknown
-
2011
- 2011-11-25 ZA ZA2011/08697A patent/ZA201108697B/en unknown
- 2011-12-25 IL IL217197A patent/IL217197A/en active IP Right Grant
-
2012
- 2012-02-09 CO CO12022608A patent/CO6440512A2/es not_active Application Discontinuation
- 2012-02-16 CL CL2012000412A patent/CL2012000412A1/es unknown
- 2012-03-12 MA MA34683A patent/MA33581B1/fr unknown
-
2013
- 2013-06-21 US US13/923,858 patent/US20130296365A1/en not_active Abandoned
-
2016
- 2016-03-17 SM SM201600077T patent/SMT201600077B/xx unknown
- 2016-04-05 CY CY20161100273T patent/CY1117481T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL217197A0 (en) | Quinoline derivative-containing pharmaceutical composition | |
| ZA201107776B (en) | Pharmaceutical composition | |
| SG2014012405A (en) | Pharmaceutical compositions | |
| EP2379077A4 (en) | PHARMACEUTICAL COMPOSITION | |
| PL2654736T3 (pl) | Nowa kompozycja farmaceutyczna | |
| ZA201109138B (en) | Pharmaceutical composition having improved solubility | |
| GB0902648D0 (en) | Pharmaceutical compounds and compositions | |
| IL219018A0 (en) | Pharmaceutical compositions | |
| GB0919650D0 (en) | Pharmaceutical composition | |
| GB0908317D0 (en) | Pharmaceutical compounds and compositions | |
| GB0902428D0 (en) | Pharmaceutical methods & compositions | |
| GB0921139D0 (en) | Pharmaceutical methods & compositions | |
| HU0900010D0 (en) | Improved pharmaceutical composition | |
| GB0910225D0 (en) | Pharmaceutical compositions | |
| AU2009905147A0 (en) | Pharmaceutical Compositions | |
| HK1174530A (en) | Pharmaceutical compositions | |
| GB0908970D0 (en) | Local pharmaceutical compositions | |
| GB0919055D0 (en) | Pharmaceutical compounds and compositions | |
| GB0908069D0 (en) | Pharmaceutical compounds and compositions | |
| GB0903945D0 (en) | Pharmaceutical compounds and compositions | |
| GB0902651D0 (en) | Pharmaceutical compounds and compositions |